
CEL-SCI (CVM) announced positive new pre-surgical tumor response and safety analyses from its completed Phase 3 study of Multikine. The findings were presented by the Company’s Chief Scientific Officer and
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| CVM | Cel-Sci | 1.85 | -4.84 | -72.35% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.85 | -72.35% |

CEL-SCI (CVM) announced positive new pre-surgical tumor response and safety analyses from its completed Phase 3 study of Multikine. The findings were presented by the Company’s Chief Scientific Officer and

CEL-SCI (CVM) Corporation announced that the Company’s Chief Scientific Officer, Dr. Eyal Talor, has been invited to deliver a keynote presentation at the 6th World Congress on Otology, Rhinology and

Wall Street traded slightly lower Monday as investors awaited a heavy retail earnings slate, including Home Depot (HD), Target (TGT), and Walmart (WMT), while geopolitical tensions and shifting Fed expectations

“This was a quarter of important progress across our clinical, regulatory and commercialization programs as we move Multikine closer to patients,” stated CEL-SCI (CVM) CEO Geert Kersten. “Our recently published

CEL-SCI (CVM) announced the publication of its study, “A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival in Oral Cancer Patients with Low Tumor PD-L1 Expression: The IT-MATTERS Clinical Trial –

CEL-SCI (CVM) announced that a manuscript highlighting the latest findings from its Phase 3 study titled “A Novel Neoadjuvant Immunotherapy Confers Improved Overall Survival in Oral Cancer Patients with Low

CEL-SCI (CVM) Corporation announced it is launching its global Confirmatory Registration Study of Multikine as a neoadjuvant treatment for newly diagnosed, previously untreated, resectable, locally advanced primary head and neck

CEL-SCI (CVM) announced the successful conclusion of a formal signing ceremony with Saudi Amarox during the BIO International Convention 2026 on June 22nd in San Diego. Under the agreement, Amarox

CEL-SCI (CVM) highlighted its dual-track strategy to bring Multikine to patients with newly diagnosed locally advanced head and neck cancer through parallel regulatory initiatives in the U.S. and Saudi Arabia.

CEL-SCI (CVM) Corporation announced it will participate in a formal signing ceremony with Saudi Amarox during the BIO International Convention 2026 in San Diego, California. The ceremony will mark a
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Dec 23, 2026TBA | $29.20M | ― | ― | 0.03 | -0.64 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.